Headline: Servier India launches subsidised biomarker testing for IDH-mutated AML and cholangiocarcinoma
Bullet Points:
- Initiative offers a customised biomarker test panel for Acute Myeloid Leukaemia (AML) and Cholangiocarcinoma (CCA) across India at subsidised rates
- IDH1 and IDH2 mutation tests for both cancers provided free of cost to patients in the government sector
- Partnership involves Servier India, MedGenome and Strand Life Sciences to expand molecular testing access beyond urban centres
- Programme launched under Servier Care patient-support platform providing financial assistance and subsidised diagnostics where legally permissible
- Early molecular testing aims to guide precision oncology treatment decisions and improve survival rates in AML and CCA